Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Corcia, P.
Right arrow Articles by Bacq, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corcia, P.
Right arrow Articles by Bacq, Y.
Related Collections
Right arrow Viral infections
Right arrow Chronic inflammatory demyelinating polyneuropathy
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2004;63:179-180
© 2004 American Academy of Neurology
Brief Communications

Improvement of a CIDP associated with hepatitis C virus infection using antiviral therapy

P. Corcia, MD PhD, D. Barbereau, MD, A. M. Guennoc, MD, B. de Toffol, MD PhD and Y. Bacq, MD

From the Department of Neurology (Drs. Corcia, Guennoc, and de Toffol), CHRU Bretonneau, and Department of Hepatogastroenterology (Drs. Barbereau and Bacq), CHRU Trousseau, Tours, France.

Address correspondence and reprint requests to Dr. P. Corcia, Service de Neurologie, CHRU Bretonneau, 2 bis Boulevard Tonnellé, 37044 Tours Cedex, France; e-mail: corcia{at}med.univ-tours.fr

A 57-year-old man with chronic inflammatory demyelinating polyneuropathy associated with hepatitis C virus infection was treated successfully with the combination of peginterferon-{alpha}-2b and ribavirin. Viral eradication was confirmed during the 4th week of treatment and was followed 3 weeks later by neurologic improvement. The patient resumed normal activity 1 year after the therapy was completed.

Received November 20, 2003. Accepted in final form February 23, 2004.




This article has been cited by other articles:


Home page
 Mult SclerHome page
R. Hoftberger, F. Garzuly, H.P. Dienes, J. Grubits, B. Rohonyi, G. Fischer, Z. Hanzely, H. Lassmann, and H. Budka
Fulminant central nervous system demyelination associated with interferon-{alpha} therapy and hepatitis C virus infection
Multiple Sclerosis, November 1, 2007; 13(9): 1100 - 1106.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. Briani, L. Chemello, G. Zara, M. Ermani, E. Bernardinello, S. Ruggero, E. Toffanin, A. Gatta, L. Battistin, and L. Cavalletto
Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV.
Neurology, September 12, 2006; 67(5): 781 - 785.
[Abstract] [Full Text] [PDF]